CP4-20520-76087
3 vaccinations
1 coded response
12 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 461 / IN
- Registered
- 2022-02-05
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-04-14
Dose 1 — Pfizer-BioNTech
-
2021-05-05
Dose 2 — Pfizer-BioNTech
-
2022-02-05
Registered in v-safe
-
2022-02-06
Dose 3 — Moderna
- 2022-02-06
-
2022-02-07
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2022-02-08
- 2022-02-10
- 2022-02-13
- 2022-02-21
- 2022-02-28
- 2022-03-06
- 2022-03-13
- 2022-03-22
- 2022-05-09
-
2022-08-07
Survey response — 6 months, dose 3MedDRA: Oropharyngeal pain, Rhinorrhoea — Feeling: GoodFree text: Temporary runny nose and sore throat.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-04-14 | Pfizer-BioNTech | No |
| 2 | 2021-05-05 | Pfizer-BioNTech | No |
| 3 | 2022-02-06 | Moderna | No |
Free text
Release 12 — 6 months, dose 3
Symptoms: Temporary runny nose and sore throat.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release